Gain Therapeutics (GANX) Registration Filing summary

Company overview and business model

• Focuses on developing novel small molecule therapeutics for CNS disorders, lysosomal storage disorders, metabolic disorders, and oncology through protein degradation strategies.

• Lead candidate GT-02287 targets Parkinson's disease and is in Phase 1b clinical trials, with promising preclinical and Phase 1 safety and efficacy data.

• Utilizes the Magellan™ computational platform to identify allosteric binding sites and design proprietary small molecules, enabling rapid and cost-effective pipeline expansion.

• Incorporated in Delaware in 2020, with principal offices in Bethesda, MD.

Financial performance and metrics

• As of May 1, 2025, public float was $62,723,431, based on 28,772,216 shares held by non-affiliates at $2.18 per share.

• Last reported sale price for common stock on May 27, 2025, was $1.77 per share on Nasdaq.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital and general corporate purposes.

• Pending use, proceeds may be invested in short-term, interest-bearing or investment-grade securities.